Results for: Medication shortage

Hims & Hers Health, Inc. (HIMS) has launched a GLP-1 Supply Tracker to highlight and address the growing difficulty Americans face in accessing branded GLP-1 medications for obesity. The tracker, which has already received nearly 7,000 reports in its first week, aims to provide valuable data to the FDA and advocate for improved healthcare access.

The DEA has authorized a significant increase in Vyvanse production to address the ongoing shortage of ADHD medications in the U.S. and abroad. The move follows an FDA request and aims to meet both domestic and international demand.